ProBioGen signs commercial licence agreement with AstraZeneca for using GlymaxX technology
Following evaluation of the technology under a research license, AstraZeneca will now continue to use GlymaxX and will integrate…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
GlymaxX Technology
ProBioGen licenses GlymaxX Technology to Bayer
Bayer will leverage the technology to further increase the potency of an undisclosed antibody candidate for oncological…